Proof-of-concept Study for Bio-marker Assay Validation in Humans

Martin Angst1 site in 1 country13 target enrollmentSeptember 16, 2005

ConditionsSkin Diseases

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Skin Diseases
Sponsor: Martin Angst
Enrollment: 13
Locations: 1
Primary Endpoint: Cytokine-release profile in response to inflammation, noxious heat, and asministration of a COX-inhibitor
Status: Completed
Last Updated: 12 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This study aims to establish a novel approach assisting the rational development of analgesic and anti-inflammatory drugs. In a first step we will test in healthy human volunteers whether proteins mediating inflammation and pain can be detected in an experimentally induced inflammatory skin lesion. Fluids that will be used to detect such proteins will be collected from the inflamed skin site via small porous catheters. We wish to establish the expression pattern of different proteins and correlate it with various tests assessing pain.

Registry

clinicaltrials.gov

Start Date

September 16, 2005

End Date

TBD

Last Updated

12 years ago

Study Type

Interventional

Study Design

Crossover

Sex

All

Investigators

Sponsor

Martin Angst

Responsible Party

Sponsor Investigator

Principal Investigator

Martin Angst

Professor of Anesthesia

Stanford University

Eligibility Criteria

Inclusion Criteria

•Age between 21-
•Skin type II or III according to the classification of Fitzpatrick (II: fair skin, always burns, sometimes tans, III: medium skin, sometimes burns, always tans).\

Exclusion Criteria

•History of a significant systemic disease, a dermatological disease, bleeding disorder, or chronic pain.
•Consumption of analgesic drugs.
•Hypersensitivity to sunlight.